Chemo, Immunotherapy Combo May Help Fight Liver Cancer, Study Says
Combining the chemotherapy agent Sutent (sunitinib) and immunotherapy may be a promising strategy to fight hepatocellular carcinoma, the most common type of liver cancer, according…
Liver cancer
Tivantinib Provides No Survival Benefit in Hepatocellular Carcinoma Patients, Phase 3 Study Shows
Tivantinib, an experimental oral inhibitor of the MET receptor, is not better than best supportive care in patients with inoperable hepatocellular carcinoma (HCC) who are intolerant or…
